Day One Biopharmaceuticals, Inc.: M&A transaction — Day One sells Rare Pediatric Disease PRV for $108M; $8.1M to Viracta

Day One Biopharmaceuticals, Inc.

Closed sale of Priority Review Voucher for $108M in cash on May 29, 2024.
PRV awarded after FDA accelerated approval of OJEMDA (tovorafenib) on April 23, 2024.
$8.1M of proceeds will be paid to Viracta to fully satisfy PRV-related obligations.
Proceeds provide non-dilutive capital to fund OJEMDA launch and clinical development.

item 1.01 item 2.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Day One Biopharmaceuticals, Inc. completed a disposition for $108.0 million (closed 2024-05-29).

Action: disposition
Consideration: $108.0 million
Closing: 2024-05-29

Exact text from the filing

pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for $108.0 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-24-149895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.